Table 3.

Treatment of ICPi-AKI with glucocorticoids, stratified by renal recovery

Treatment VariableAll (n=119)Complete Recovery (n=53)Partial or No Recovery (n=66)P Value
SCr at GC initiation, mg/dl3.01 (2.25–4.48)3.34 (2.29–4.63)2.89 (2.24–3.81)0.44
Required RRT at GC initiation, n (%)3 (3)1 (2)2 (3)0.99
Treatment delay, da3 (0–8)3 (1–8)3 (0–8)0.70
Received IV pulse GC, n (%)36 (30)19 (36)17 (26)0.32
Grams of solumedrol1.00 (0.38–2.03)1.00 (0.38–1.50)1.0 (0.41–2.88)0.99
Initial daily oral GC dose (mg of prednisone)60 (60–80)60 (60–80)60 (60–80)0.97
Days at initial oral GC dose7 (5–12)7 (5–10)7 (5–13)0.73
Days at >20 mg oral prednisone28 (16–47)26 (16–39)31 (17–49)0.52
Cumulative oral GC dose in first 2 wk (mg of prednisone)780 (600–980)775 (658–955)780 (570–980)0.78
Days of oral GC63 (32–107)62 (35–98)67 (28–119)0.96
Received non-GC immunosuppressant, n (%)b11 (9)4 (8)7 (11)0.75
Nadir SCr after treatment, mg/dlc1.40 (1.06–1.73)1.08 (0.9–1.40)1.6 (1.40–1.90)<0.001
  • Data are shown as median (IQR) and n (%). GC, glucocorticoids; IV, intravenous.

  • a Denotes time from doubling of SCr to initiation of GCs.

  • b Non-GC immunosuppression included mycophenolate mofetil (n=7), rituximab (n=2), cyclophosphamide (n=1), and eculizumab (n=1).

  • c Defined as the lowest value achieved within 3 months after the AKI episode (excluding values obtained during RRT).